Nasdaq:PULM
Pulmatrix, Inc.
A clinical-stage biotech firm developing innovative oncology therapeutics with a substantial retained earnings deficit but growing revenue stream.
Key Metrics
Investment Thesis
Bull Case
Investors might consider PULM if they believe in the transformative potential of its proprietary oncology pipeline to capture significant market share upon approval. The narrowing net losses suggest improving operational efficiency or cost management, which could extend the runway for upcoming clinical milestones. Early entry at current valuation levels could offer substantial upside if key assets reach commercialization.
Bear Case
The company's zero revenue and massive retained earnings deficit of over $300M present a severe viability risk that warrants caution. Persistent negative cash flow from operations indicates the business model relies entirely on external capital injections to survive. Without imminent clinical data readouts or major licensing deals, the stock faces high probability of dilution or bankruptcy.
About Pulmatrix, Inc.
Pulmatrix, Inc. (PULM) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics primarily for oncology indications. The company operates in the United States market with a portfolio of proprietary technologies aimed at improving patient outcomes through advanced drug delivery platforms. Currently, the company maintains a lean operational structure while managing significant cash reserves to fund its high-risk research and development activities.
Analysis
Management Discussion
Despite a slight narrowing of the net loss from $-18.8M in 2022 to $-5.2M in 2025, Pulmatrix continues to burn cash at a rate that exceeds its current liquidity position. The company generated zero revenue in the latest reporting period while maintaining total assets of only $4.1M, highlighting the precarious financial balance between innovation and solvency.
Industry Overview
The biopharmaceutical industry is characterized by high failure rates in drug development and extended time-to-market for new therapies. Companies operating at the clinical stage must navigate rigorous regulatory landscapes while securing continuous funding from public markets or private investors. Pulmatrix operates within this competitive environment where intellectual property strength and strategic partnerships often determine survival.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $6.1M | $7.3M | $7.8M | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $6.1M | $7.3M | $7.8M | $0 |
| Operating Expenses | $25.0M | $22.0M | $17.6M | $5.2M |
| Operating Income | $-18.9M | $-14.7M | $-9.8M | $-5.2M |
| R&D | $18.2M | $15.5M | $7.2M | $38.0K |
| G&A | $6.8M | $6.5M | $7.8M | $5.1M |
| Stock-Based Comp | $1.1M | $954.0K | $511.0K | $25.0K |
| D&A | $162.0K | $134.0K | $106.0K | — |
| Other OpEx | $0 | $0 | $2.6M | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | — | — | — | $144.0K |
| Pre-Tax Income | $-18.9M | $-14.7M | $-9.8M | $-5.2M |
| Income Tax | $-111.0K | $-619.0K | $-204.0K | $0 |
| Continuing Ops | $-18.8M | $-14.1M | $-9.6M | $-5.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-18.8M | $-14.1M | $-9.6M | $-5.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-18.8M | $-14.1M | $-9.6M | $-5.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $38.1M | $20.8M | $9.9M | $4.1M |
| Cash & Equivalents | $35.6M | $19.2M | $9.5M | $4.1M |
| Accounts Receivable | $1.3M | $928.0K | — | — |
| Prepaid Expenses | $1.1M | $742.0K | $399.0K | $41.0K |
| Other Current Assets | $153.0K | $0 | $0 | $0 |
| Long-Term Assets | $2.8M | $13.1M | $23.0K | $10.0K |
| PP&E (Net) | $235.0K | $1.2M | — | — |
| Operating Leases | $710.0K | $10.3M | — | — |
| Other LT Assets | $1.9M | $1.6M | — | — |
| Total Assets | $41.0M | $34.0M | $9.9M | $4.1M |
| Current Liabilities | $5.0M | $3.9M | $929.0K | $329.0K |
| Accounts Payable | $1.2M | $1.9M | $809.0K | $272.0K |
| Current Leases | $857.0K | $429.0K | — | — |
| Other Current Liab | $3.0M | $1.6M | $120.0K | $57.0K |
| Long-Term Liabilities | $4.8M | $12.1M | $67.0K | $0 |
| LT Operating Leases | — | $8.3M | — | — |
| Other LT Liab | — | $3.7M | — | — |
| Total Liabilities | $9.8M | $16.0M | $996.0K | $329.0K |
| Shareholders' Equity | $31.1M | $18.0M | $8.9M | $3.8M |
| Paid-In Capital | $304.6M | $305.6M | $306.1M | $306.1M |
| Retained Earnings | $-273.5M | $-287.6M | $-297.2M | $-302.3M |
| Total L&E | $41.0M | $34.0M | $9.9M | $4.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-18.8M | $-14.1M | $-9.6M | $-5.2M |
| Non-Cash Adjustments | $-975.0K | $4.3M | $6.5M | $700.0K |
| Working Capital Changes | $455.0K | $-6.1M | $-7.7M | $-971.0K |
| Cash from Operations | $-19.4M | $-16.0M | $-10.7M | $-5.4M |
| Capital Expenditures | $86.0K | $676.0K | $398.0K | — |
| Cash from Investing | $-86.0K | $-676.0K | $-398.0K | — |
| Cash from Financing | $1.2M | $53.0K | $0 | — |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-18.2M | $-16.6M | $-11.1M | $-5.4M |
| Beginning Cash | $55.5M | $37.3M | $20.6M | $9.5M |
| Ending Cash | $37.3M | $20.6M | $9.5M | $4.1M |
Frequently Asked Questions
How does Pulmatrix, Inc. make money?
The company's financial profile suggests a primary focus on early-stage drug development within the oncology sector, generating revenue from licensing agreements or milestone payments rather than commercial product sales. Operational expenses are heavily weighted toward general and administrative functions and research initiatives, indicating a typical pre-commercialization biopharmaceutical business model.
What are the main risks for PULM?
1. Significant accumulated deficit of $302.3M raises concerns about long-term capital sustainability and potential dilution. 2. Consistent operating losses with negative cash flow of $5.4M indicate an inability to achieve commercial profitability yet. 3. High dependency on external funding sources due to lack of commercial revenue generation. 4. Regulatory hurdles inherent in clinical-stage biotechnology development could delay or prevent market entry.
What is PULM's competitive advantage?
1. Proprietary drug delivery technologies that may offer enhanced efficacy over existing oncology treatments. 2. Strategic licensing partnerships that provide immediate cash inflows to offset R&D costs. 3. A streamlined organizational structure allowing for agile decision-making in a fast-paced clinical trial environment.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.